Table 1.
Characteristics of the examined number of patients in disease-stratified groups.
| No. of subjects | Age (yr) | Female/Male | Smokers/non-smokers | |
|---|---|---|---|---|
| Sarcoidosis | 83 | 40 ± 12 | 35/48 | 20/63 |
| IPF | 31 | 61 ± 12 | 14/17 | 9/22 |
| EAA | 29 | 47 ± 16 | 13/16 | 8/21 |
| CVD | 16 | 55 ± 11 | 7/9 | 4/12 |
| SCL | 13 | 51 ± 12 | 11/2 | 1/12 |
| WG | 14 | 49 ± 18 | 12/2 | 3/11 |
| PLH | 12 | 37 ± 13 | 4/8 | 12/0 |
| Silicosis | 12 | 43 ± 9 | 1/11 | 8/4 |
| DIPF | 10 | 63 ± 11 | 3/7 | 1/9 |
| COP | 5 | 58 ± 8 | 3/2 | 1/4 |
| Healthy volunteers | 36 | 39 ± 11 | 22/14 | 4/32 |
IPF - idiopathic pulmonary fibrosis, EAA - extrinsic allergic alveolitis, CVD - collagen vascular diseases, SCL - scleroderma, WG - Wegener's granulomatosis, PLH - pulmonary Langerhans cells histiocytosis, DIPF - drug-induced pulmonary fibrosis, COP - cryptogenic organizing pneumonia.